About Merus N.V. (NASDAQ:MRUS)
Merus NV is a biotechnology company based in the Netherlands. The Company develops differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Biclonics format. Its products inlcude, among others, MCLA-134 that is designed to bind to a combination of two immunomodulatory targets expressed by T cells, as wellas MCLA-145 that is designed to bind to a tumor-associated target with an immunomodulatory target involved in checkpoint inhibition.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:MRUS
- CUSIP: N/A
- Web: www.merus.nl
Capitalization:- Market Cap: $339.04 million
- Outstanding Shares: 19,392,000
Average Prices:- 50 Day Moving Avg: $18.80
- 200 Day Moving Avg: $18.80
- 52 Week Range: $13.13 - $33.63
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -5.17
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $8.52 million
- Price / Sales: 39.79
- Book Value: $4.51 per share
- Price / Book: 3.88
Profitability:- EBITDA: ($44,610,000.00)
- Net Margins: -909.21%
- Return on Equity: -100.87%
- Return on Assets: -43.74%
Debt:- Current Ratio: 12.91%
- Quick Ratio: 12.91%
Misc:- Average Volume: 40,414 shs.
- Beta: 0.3
- Short Ratio: 15.65
Frequently Asked Questions for Merus N.V. (NASDAQ:MRUS)
What is Merus N.V.'s stock symbol?
Merus N.V. trades on the NASDAQ under the ticker symbol "MRUS."
When will Merus N.V. make its next earnings announcement?
Where is Merus N.V.'s stock going? Where will Merus N.V.'s stock price be in 2017?
4 equities research analysts have issued 1 year target prices for Merus N.V.'s shares. Their forecasts range from $28.00 to $32.00. On average, they expect Merus N.V.'s stock price to reach $30.50 in the next twelve months. View Analyst Ratings for Merus N.V..
What are analysts saying about Merus N.V. stock?
Here are some recent quotes from research analysts about Merus N.V. stock:
- 1. According to Zacks Investment Research, "Merus B.V. is a clinical-stage immuno-oncology company developing bispecific antibody therapeutics, referred to as Biclonics. The company's bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 1/2 clinical trial as a potential treatment for HER2-expressing solid tumors; MCLA-117, is being developed as a potential treatment for acute myeloid leukemia and MCLA-158, which is designed to bind to cancer stem cells and is being developed as a potential treatment for colorectal cancer and other solid tumors. Merus B.V. is headquartered in Utrecht, the Netherlands. " (10/11/2017)
- 2. Jefferies Group LLC analysts commented, "Lead mAbs '128 and '117 remain early; initial data this year (likely ASCO/ASH) could provide some signals though may be early to definitively interpret. We continue to see promise though, and particularly striking from our mtgs was the potential de-risking advantages their bispecific format and capabilities will provide as the pipeline matures'something we view as underappreciated. Raise tgt to $33 to better reflect LT potential." (2/17/2017)
Who are some of Merus N.V.'s key competitors?
Some companies that are related to Merus N.V. include Adaptimmune Therapeutics PLC (ADAP), MacroGenics (MGNX), Paratek Pharmaceuticals (PRTK), Synergy Pharmaceuticals (SGYP), G1 THERAPEUTICS (GTHX), Axovant Sciences Ltd (AXON), Achaogen (AKAO), Calithera Biosciences (CALA), Achillion Pharmaceuticals (ACHN), Madrigal Pharmaceuticals (MDGL), Insys Therapeutics (INSY), Karyopharm Therapeutics (KPTI), Aurinia Pharmaceuticals (AUPH), uniQure N.V. (QURE), Clementia Pharmaceuticals (CMTA), Rigel Pharmaceuticals (RIGL), Sucampo Pharmaceuticals (SCMP) and Jounce Therapeutics (JNCE).
Who are Merus N.V.'s key executives?
Merus N.V.'s management team includes the folowing people:
- Mark T. Iwicki, Chairman of the Supervisory Board
- Ton Logtenberg, Chief Executive Officer
- John J. Crowley CPA, Chief Financial Officer, Executive Vice President
- Shelley Margetson, Chief Operating Officer, Executive Vice President
- John de Kruif, Chief Technology Officer
- Saterah Shamsili, Chief Marketing Officer
- Mark Throsby, Chief Scientific Officer
- Lex Bakker, Chief Development Officer
- Ellen Broug, Secretary to the Supervisory Board
- Wolfgang Berthold, Member of the Supervisory Board
When did Merus N.V. IPO?
(MRUS) raised $64 million in an initial public offering on Thursday, May 19th 2016. The company issued 4,300,000 shares at $14.00-$16.00 per share. Citigroup and Jefferies acted as the underwriters for the IPO and Guggenheim Securities and Wedbush PacGrow were co-managers.
Who owns Merus N.V. stock?
How do I buy Merus N.V. stock?
Shares of Merus N.V. can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Merus N.V.'s stock price today?
One share of Merus N.V. stock can currently be purchased for approximately $17.48.
MarketBeat Community Rating for Merus N.V. (NASDAQ MRUS)MarketBeat's community ratings are surveys of what our community members think about Merus N.V. and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Merus N.V. (NASDAQ:MRUS) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Hold Rating, 3 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.75) |
| Consensus Price Target: | $30.50 (74.49% upside) |
Consensus Price Target History for Merus N.V. (NASDAQ:MRUS)
Analysts' Ratings History for Merus N.V. (NASDAQ:MRUS)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 10/18/2017 | Royal Bank Of Canada | Reiterated Rating | Buy | $28.00 | N/A |  |
| 7/14/2017 | Jefferies Group LLC | Reiterated Rating | Buy | $31.00 | Low | |
| 6/6/2017 | Wedbush | Reiterated Rating | Outperform | $32.00 | High | |
| 3/21/2017 | Citigroup Inc. | Downgrade | Buy -> Neutral | $31.00 | High | |
| 6/13/2016 | Guggenheim | Initiated Coverage | Buy | $18.00 | N/A | |
(Data available from 10/20/2015 forward)
Earnings History for Merus N.V. (NASDAQ:MRUS)Earnings History by Quarter for Merus N.V. (NASDAQ MRUS)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/6/2017 | | | | | | | | |
| 11/7/2016 | Q3 | ($0.51) | ($0.31) | | $1.32 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Merus N.V. (NASDAQ:MRUS)2017 EPS Consensus Estimate: $0.82
2018 EPS Consensus Estimate: ($5.10)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 2 | $0.08 | $5.61 | $2.85 |
| Q2 2017 | 2 | ($0.72) | ($0.55) | ($0.64) |
| Q3 2017 | 2 | ($0.77) | ($0.55) | ($0.66) |
| Q4 2017 | 2 | ($0.92) | ($0.55) | ($0.74) |
| Q1 2018 | 1 | ($1.11) | ($1.11) | ($1.11) |
| Q2 2018 | 1 | ($1.21) | ($1.21) | ($1.21) |
| Q3 2018 | 1 | ($1.33) | ($1.33) | ($1.33) |
| Q4 2018 | 1 | ($1.45) | ($1.45) | ($1.45) |
(Data provided by Zacks Investment Research)
Dividend History for Merus N.V. (NASDAQ:MRUS)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Merus N.V. (NASDAQ:MRUS)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Merus N.V. (NASDAQ:MRUS)
Latest Headlines for Merus N.V. (NASDAQ:MRUS)
| Source: |
|
| Date | Headline |
|---|
 | Contrasting Versartis (VSAR) and Merus N.V. (MRUS)
www.americanbankingnews.com - October 18 at 4:24 PM |
| Merus N.V. (MRUS) Receives "Buy" Rating from Royal Bank Of Canada
www.americanbankingnews.com - October 18 at 12:04 PM |
| Merus N.V. (MRUS) Expected to Post Earnings of -$0.69 Per Share
www.americanbankingnews.com - October 12 at 4:24 PM |
| Merus N.V. (MRUS) Downgraded to "Sell" at Zacks Investment Research
www.americanbankingnews.com - October 11 at 6:32 AM |
 | Merus N.V.: Merus to Participate in the BIO Investor Forum
www.finanznachrichten.de - October 11 at 5:38 AM |
| Merus N.V. (MRUS) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - October 9 at 2:42 AM |
 | Merus NV :MRUS-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017
finance.yahoo.com - October 6 at 9:24 AM |
| Merus’ Intellectual Property Portfolio Expands with Two New Patents For its Biclonics® Technology
finance.yahoo.com - September 22 at 9:03 AM |
| Merus N.V. (MRUS) to Post Q3 2017 Earnings of ($0.77) Per Share, Wedbush Forecasts
www.americanbankingnews.com - September 22 at 6:36 AM |
| Merus N.V. (MRUS) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - September 14 at 6:50 PM |
| Royal Bank Of Canada Initiates Coverage on Merus N.V. (MRUS)
www.americanbankingnews.com - September 14 at 5:26 PM |
| Merus NV breached its 50 day moving average in a Bullish Manner : MRUS-US : September 8, 2017
finance.yahoo.com - September 9 at 6:26 AM |
| Merus N.V.: Merus to Participate in Two Investor Conferences in September 2017
www.finanznachrichten.de - August 31 at 7:29 AM |
| Merus to Participate in Two Investor Conferences in September 2017
finance.yahoo.com - August 31 at 7:29 AM |
| Merus NV – Value Analysis (NASDAQ:MRUS) : August 15, 2017
finance.yahoo.com - August 16 at 6:20 AM |
| Merus to Present at the 2017 Wedbush PacGrow Healthcare Conference
finance.yahoo.com - August 10 at 6:03 AM |
| Merus NV breached its 50 day moving average in a Bullish Manner : MRUS-US : August 2, 2017
finance.yahoo.com - August 3 at 5:58 AM |
| Merus NV breached its 50 day moving average in a Bullish Manner : MRUS-US : August 2, 2017
finance.yahoo.com - August 3 at 5:58 AM |
| $2.59 Million in Sales Expected for Merus N.V. (NASDAQ:MRUS) This Quarter
www.americanbankingnews.com - August 1 at 9:23 AM |
 | U.S. Court of Appeals for the Federal Circuit Affirms Merus’ Inequitable Conduct Claim Against Regeneron
www.nasdaq.com - July 29 at 4:46 AM |
| Merus NV :MRUS-US: Earnings Analysis: Q1, 2017 By the Numbers : July 14, 2017
finance.yahoo.com - July 15 at 6:39 AM |
| Merus N.V.'s (MRUS) "Buy" Rating Reiterated at Jefferies Group LLC
www.americanbankingnews.com - July 15 at 12:56 AM |
| Merus N.V. (MRUS) to Post Q2 2017 Earnings of ($0.72) Per Share, Wedbush Forecasts
www.americanbankingnews.com - July 14 at 12:16 PM |
| Wedbush Weighs in on Merus N.V.'s Q1 2018 Earnings (NASDAQ:MRUS)
www.americanbankingnews.com - July 13 at 1:30 PM |
| Edited Transcript of MRUS earnings conference call or presentation 11-Jul-17 8:30pm GMT
finance.yahoo.com - July 13 at 6:57 AM |
| Merus N.V.: Merus Announces First Quarter 2017 Financial Results and Mid-Year Operating Results
www.finanznachrichten.de - July 12 at 5:04 AM |
| Investor Network: Merus N.V. to Host Earnings Call
www.nasdaq.com - July 12 at 5:04 AM |
| Merus to Report First Quarter 2017 Financial & Mid-Year Operating Results on July 11, 2017
finance.yahoo.com - July 7 at 7:32 AM |
 | Earnings Scheduled For April 3, 2017
feeds.benzinga.com - April 3 at 4:52 AM |
 | Merus N.V. (MRUS) Enters Research Collaboration with Institute for Research in Biomedicine
www.streetinsider.com - January 5 at 8:05 PM |
 | Merus NV breached its 50 day moving average in a Bullish Manner : MRUS-US : December 22, 2016
us.rd.yahoo.com - December 23 at 6:51 PM |
 | Merus upgraded by Citigroup
us.rd.yahoo.com - December 23 at 6:51 PM |
| 7:02 am Merus and Incyte (INCY) enter collaboration agreement for its Biclonics platform; Incyte to make up-front payment of $120 mln and purchase $80 mln of Merus common shares
us.rd.yahoo.com - December 21 at 10:03 AM |
Merus N.V. (MRUS) Chart for Friday, October, 20, 2017
